Figure 5. Proteasome inhibition with ixazomib results in similar levels of tumor cell apoptosis compared with bortezomib in human melanoma cell lines.
BRAF V600E mutant (A375) and BRAF wild-type (WM1366) human melanoma tumor cells plated at a density of 2 × 105 cells/well on 6 well plates were treated for 24 or 48 hours with complete medium supplemented with either 35 nM ixazomib or 10 nM bortezomib. After incubation, the cells were subjected to annexin V/propidium iodide staining and flow cytometric analysis to determine the levels of apoptosis.